Evidence map›Paper›PMID 32727068›Full record

ReviewMedicina (Kaunas, Lithuania)2020

Prognostic Markers of Myelodysplastic Syndromes.

Yuliya Andreevna Veryaskina, Sergei Evgenievich Titov, Igor Borisovich Kovynev, Tatiana Ivanovna Pospelova, Igor Fyodorovich Zhimulev

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. RNA Splicing as a Therapeutic Target in Cancer.Annual review of pharmacology and toxicology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Yuliya Andreevna VeryaskinaLaboratory of Gene Engineering, Institute of Cytology and Genetics, SB RAS, 630090 Novosibirsk, Russia.ORCID 0000-0002-3799-9407
Sergei Evgenievich TitovDepartment of the Structure and Function of Chromosomes, Laboratory of Molecular Genetics, Institute of Molecular and Cellular Biology, SB RAS, 630090 Novosibirsk, Russia.ORCID 0000-0001-9401-5737
Igor Borisovich KovynevDepartment of Therapy, Hematology and Transfusiology, Novosibirsk State Medical University, 630091 Novosibirsk, Russia.
Tatiana Ivanovna PospelovaDepartment of Therapy, Hematology and Transfusiology, Novosibirsk State Medical University, 630091 Novosibirsk, Russia.
Igor Fyodorovich ZhimulevDepartment of the Structure and Function of Chromosomes, Laboratory of Molecular Genetics, Institute of Molecular and Cellular Biology, SB RAS, 630090 Novosibirsk, Russia.
Novosibirsk State Medical University · RUInstitute of Cytology and Genetics · RUInstitute of Molecular and Cell Biology · RUState Research Center of Virology and Biotechnology VECTOR · RU

Funding

Russian Foundation for Basic Research 19-34-60024
6 · The paper itself

Abstract

Myelodysplastic syndrome (MDS) is a clonal disease characterized by multilineage dysplasia, peripheral blood cytopenias, and a high risk of transformation to acute myeloid leukemia. In theory, from clonal hematopoiesis of indeterminate potential to hematologic malignancies, there is a complex interplay between genetic and epigenetic factors, including miRNA. In practice, karyotype analysis assigns patients to different prognostic groups, and mutations are often associated with a particular disease phenotype. Among myeloproliferative disorders, secondary MDS is a group of special entities with a typical spectrum of genetic mutations and cytogenetic rearrangements resembling those in de novo MDS. This overview analyzes the present prognostic systems of MDS and the most recent efforts in the search for genetic and epigenetic markers for the diagnosis and prognosis of MDS.

Indexed as

PrognosisBiomarkersCore Binding Factor Alpha 2 SubunitDioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AHumansMutationMyelodysplastic SyndromesPhosphoproteinsProto-Oncogene ProteinsRepressor ProteinsRNA Splicing FactorsSerine-Arginine Splicing FactorsASXL1 protein, humanBiomarkersCore Binding Factor Alpha 2 SubunitDioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanPhosphoproteinsProto-Oncogene ProteinsRepressor ProteinsRNA Splicing FactorsRUNX1 protein, humanSerine-Arginine Splicing FactorsSF3B1 protein, humanSRSF2 protein, humanTET2 protein, humanacute myeloid leukemiaIPSS-RkaryotypemicroRNAmyelodysplastic syndrome

Identifiers

PMID32727068
PMCPMC7466347
OpenAlexW3045090314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.